NasdaqGM:RAPTBiotechs
Assessing RAPT Therapeutics (RAPT) Valuation After A Sharp Share Price Move
RAPT Therapeutics (RAPT) has drawn fresh attention after a sharp move in its share performance over the past 3 months. This has prompted investors to reassess the clinical stage biotech’s risk and reward profile.
See our latest analysis for RAPT Therapeutics.
At a share price of US$57.96, RAPT Therapeutics has shifted sharply over the past year, with a very large 1 year total shareholder return and a long term total shareholder return that remains negative. This suggests that recent momentum...